ArQule, Inc.

GLP toxicology testing initiated with cancer survival pathway compound

Published in Oncology Business Week, July 3rd, 2005

ArQule, Inc., (ARQL) announced that it has initiated GLP toxicology studies with ARQ 197, the lead compound of a series of proprietary compounds generated through the company's ARQ 650RP (research program) cancer survival pathway platform.

ARQ 650RP is ArQule's second major platform for oncology drug discovery, distinct from the company's E2F platform, which is partnered with Roche and includes a lead compound under investigation in several clinical trials and a second-generation compound in late preclinical development. ArQule retains ownership of all compounds based upon the ARQ 650RP platform, including ARQ 197.

"I am pleased that we have...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2005-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry